Quick filters
- Abbott Declares 357th Consecutive Quarterly Dividend PR Newswire | Friday February 15, 2013 10:58AM
- Dividend hike not out of question at Trinidad Drilling: analyst Globe and Mail | Wednesday February 13, 2013 1:26PM
- 3 top stock picks from GlobeInvest’s Christine Poole Globe and Mail | Tuesday February 12, 2013 8:00PM
- Abbott Reports Fourth-Quarter and Full-Year 2012 Results PR Newswire | Wednesday January 23, 2013 7:46AM
- Abbott and AbbVie Named to S&P Dividend Aristocrats Indices PR Newswire | Monday January 21, 2013 10:00AM
- Abbott and AbbVie Announce Investor Calls PR Newswire | Monday January 14, 2013 9:00AM
- New Abbott Test Available in Europe Provides Novel Tool to Aid Doctors in Evaluating Potential Heart Attacks PR Newswire | Wednesday January 9, 2013 7:00AM
- Abbott Initiates Clinical Trial of Absorb? in the United States PR Newswire | Tuesday January 8, 2013 8:30AM
- Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition? Drug Eluting Stent System PR Newswire | Thursday January 3, 2013 8:30AM
- Too late to buy LinkedIn, argues Barclays in downgrade Globe and Mail | Wednesday January 2, 2013 3:27PM
- Abbott Completes Separation of Research-Based Pharmaceuticals Business CNW Group | Wednesday January 2, 2013 8:11AM
- Abbott Completes Separation of Research-Based Pharmaceuticals Business PR Newswire | Wednesday January 2, 2013 7:55AM
- Abbott and AbbVie to Present at Financial Conferences PR Newswire | Friday December 21, 2012 9:00AM
- AbbVie Set to Join S&P 100 & 500; Federated Investors Set to Join S&P MidCap 400; ITT Educational Services & Procera Networks to Join S&P SmallCap 600 PR Newswire | Thursday December 20, 2012 6:08PM
- Abbott Announces New Testosterone Test to Measure the Hormone at Low Levels PR Newswire | Monday December 17, 2012 9:00AM
- Abbott Declares 356th Consecutive Quarterly Dividend PR Newswire | Friday December 14, 2012 11:50AM
- New Study Shows Promising Results For Tests That Can Help Doctors Better Evaluate Potential Heart Attacks PR Newswire | Thursday December 13, 2012 9:00AM
- Elotuzumab Progression-Free Survival Data from Phase 2 Study of Patients with Previously-Treated Multiple Myeloma Presented at 54th American Society of Hematology (ASH) Annual Meeting Business Wire | Sunday December 9, 2012 4:30PM
- Abbott Announces Effectiveness of AbbVie Form 10 Registration Statement PR Newswire | Friday December 7, 2012 5:47PM
- Abbott Board of Directors Approves Separation of AbbVie and Declares Special Dividend Distribution of AbbVie Stock PR Newswire | Wednesday November 28, 2012 4:56PM
Live Discussion of ABT on StockTwits